Camphor toxicity - Revision history

ClaireLewis at 02:14, 27 January 2019

2019-01-27T02:14:26Z

← Older revision		Revision as of 02:14, 27 January 2019
Line 6:		Line 6:

	==Clinical Features==		==Clinical Features==
	*Nausea, vomiting, abdominal pain		*[[Nausea/vomiting]], [[abdominal pain]]
	*Oral burning~~, headache~~		*Oral burning
	*Vertigo, confusion, agitation		*[[Headache]]
	*Seizure, respiratory depression, coma		*[[Vertigo]], [[confusion]], [[agitation]]
	*Hepatitis and liver failure		*[[Seizure]], respiratory depression, [[coma]]
			*[[Hepatitis]] and [[liver failure]]

	==Differential Diagnosis==		==Differential Diagnosis==
Line 20:		Line 21:
	==Management==		==Management==
	*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref>		*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref>
	*Benzodiazepines for seizure		*[[Benzodiazepines]] for seizure
	*Intubation and mechanical ventilation as needed		*[[Intubation]] and [[mechanical ventilation]] as needed
	*Charcoal not likely effective		*[[Charcoal]] not likely effective

	==Disposition==		==Disposition==

2017-09-07T05:53:36Z

← Older revision		Revision as of 05:53, 7 September 2017
Line 11:		Line 11:
	*Seizure, respiratory depression, coma		*Seizure, respiratory depression, coma
	*Hepatitis and liver failure		*Hepatitis and liver failure

			==Differential Diagnosis==


			==Evaluation==


	==Management==		==Management==
Line 17:		Line 23:
	*Intubation and mechanical ventilation as needed		*Intubation and mechanical ventilation as needed
	*Charcoal not likely effective		*Charcoal not likely effective

			==Disposition==


	==See Also==		==See Also==
	~~[[Toxicology]]~~

	==References==		==References==

2017-09-06T19:26:21Z

Background

← Older revision		Revision as of 19:26, 6 September 2017
Line 1:		Line 1:
	==Background==		==Background==
	*Common topical agent for pain relief, wart removal, osteoarthritis, cold sores		*Common topical agent for pain relief, wart removal, osteoarthritis, cold sores, cough suppression, nasal decongestion
	*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>		*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>
	*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes		*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes

2017-09-06T19:23:01Z

Background

← Older revision		Revision as of 19:23, 6 September 2017
Line 3:		Line 3:
	*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>		*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>
	*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes		*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
	*CNS ~~Stimulant~~ when ingested		*CNS stimulant when ingested

	==Clinical Features==		==Clinical Features==

2016-07-08T03:18:34Z

Text replacement - "==Treatment==" to "==Management=="

← Older revision		Revision as of 03:18, 8 July 2016
Line 12:		Line 12:
	*Hepatitis and liver failure		*Hepatitis and liver failure

	==~~Treatment~~==		==Management==
	*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref>		*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref>
	*Benzodiazepines for seizure		*Benzodiazepines for seizure

2016-04-19T21:44:53Z

← Older revision		Revision as of 21:44, 19 April 2016
Line 17:		Line 17:
	*Intubation and mechanical ventilation as needed		*Intubation and mechanical ventilation as needed
	*Charcoal not likely effective		*Charcoal not likely effective

			==See Also==
			[[Toxicology]]

	==References==		==References==

2016-04-19T21:43:20Z

Background

← Older revision		Revision as of 21:43, 19 April 2016
Line 3:		Line 3:
	*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>		*FDA limits over the counter preparations to 11%<ref>United States Food and Drug Administration. Proposed rules: external analgesic drug products for over-the-counter human use; tentative final monograph. Fed Reg 1983</ref>
	*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes		*Highly lipophilic, widely and rapidly distributed, symptom onset 5-15 minutes
			*CNS Stimulant when ingested

	==Clinical Features==		==Clinical Features==

2016-03-22T16:23:27Z

Text replacement - "Category:Tox" to "Category:Toxicology"

2016-01-22T02:12:57Z

treatment

← Older revision		Revision as of 02:12, 22 January 2016
Line 10:		Line 10:
	*Seizure, respiratory depression, coma		*Seizure, respiratory depression, coma
	*Hepatitis and liver failure		*Hepatitis and liver failure

			==Treatment==
			*Aggressive supportive care<ref>American Academy of Pediatrics Policy Statement. Camphor Revisited: Focus on Toxicity (RE9422). Pediatrics 1994;94:127-128</ref>
			*Benzodiazepines for seizure
			*Intubation and mechanical ventilation as needed
			*Charcoal not likely effective

	==References==		==References==

2016-01-22T02:05:06Z

clinical features

← Older revision		Revision as of 02:05, 22 January 2016
Line 9:		Line 9:
	*Vertigo, confusion, agitation		*Vertigo, confusion, agitation
	*Seizure, respiratory depression, coma		*Seizure, respiratory depression, coma
			*Hepatitis and liver failure

	==References==		==References==